J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
IFLScience19h
FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
Knowridge6d
These depression drugs may increase death risk in older adults
While antipsychotics can be effective for some patients, they come with well-known side effects, including an increased risk ...
BBC7mon
Antidepressant withdrawal affects one in six people
Some had been treated with antidepressants ... are more common with some antidepressants than others Official health guidance is to reduce the dose of antidepressant medication in stages over ...
US FDA approves standalone use of J&J’s ketamine-derived depression treatment
The US Food and Drug Administration (FDA) has expanded the approval for Johnson & Johnson’s nasal spray Spravato to allow its standalone use in patients with depression, the company said on Jan 21.